Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (6): 45-50.doi: 10.6040/j.issn.1671-7554.0.2021.0377

Previous Articles     Next Articles

Changes of serum IL-31 and IL-33 levels in postmenopausal patients with osteoporosis

DU Jiaojiao1, ZHUANG Xianghua1, CHEN Shihong1, WANG Xuemeng2,3, JIANG Dongqing1, WU Fei1, HAN Xiaolin2, HUA Mengyu2, SONG Yuwen1   

  1. 1. Department of Endocrinology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China;
    2. The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China;
    3. Liaocheng Peoples Hospital, Liaocheng 252000, Shandong, China
  • Published:2021-06-10

RichHTML

11

PDF (PC)

120

Abstract: Objective To analyze the changes of interleukin-31(IL-31)and interleukin-33(IL-33)levels in the serum of postmenopausal osteoporosis(PMOP)patients, and to explore the correlation between PMOP and IL-31/IL-33. Methods A total of 146 postmenopausal women were selected and their bone density was detected with double-energy X-ray absorptiometry(DXA). According to the bone density, the patients were divided into three groups: normal group, low bone mass group and osteoporosis group. Calcium(Ca), phosphorus(P), parathyroid hormone(PTH), 25-hydroxyvitamin D(［25(OH)D］), IL-31, IL-33, bone-specific alkaline phosphatase(BALP), type 1 procollagen N-terminal propeptide(P1NP), anti-tartrate acid phosphatase(TRACP-5b), and β-cross linked C-telopeptide of type 1 collagen(β-CTX)were evaluated. The differences in IL-31, IL-33 and bone turnover markers among the three groups were compared. Results In the three groups, the level of IL-31 showed an upward trend with the decrease of bone density, while the level of IL-33 reduced with the decrease of bone density(P<0.05). Multivariate Logistic regression analysis showed that in the low bone mass group, IL-33(OR: 0.987, 95%CI: 0.974-0.999, P=0.030)was statistically significant, while in the osteoporosis group, IL-31(OR: 1.019, 95%CI: 1.009-1.028, P<0.001)and IL-33(OR: 0.978, 95%CI: 0.960-0.995, P=0.013)were statistically significant. The OR value of IL-33 showed a downward trend with the decrease of bone mineral density, indicating that IL-31 and IL-33 were possible influencing factors of PMOP. Conclusion IL-31 is a possible risk factor for PMOP, while IL-33 is a possible protective factor for PMOP, suggesting that IL-31 and IL-33 play an important role in the pathogenesis of PMOP.

Key words: Postmenopausal osteoporosis, Interleukin-31, Interleukin-33, Bone mineral density, Bone turnover markers

CLC Number: 

  • R574
[1] Akkawi I, Zmerly H. Osteoporosis: current concepts [J]. Joints, 2018, 6(2): 122-127.
[2] De Martinis M, Sirufo MM, Ginaldi L. Osteoporosis: current and emerging therapies targeted to immunological checkpoints [J]. Curr Med Chem, 2020, 27(37): 6356-6372.
[3] Ponzetti M, Rucci N. Updates on osteoimmunology: whats new on the cross-talk between bone and immune system [J]. Front Endocrinol(Lausanne), 2019, 10: 236. doi: 10.3389/fendo.2019.00236.
[4] Catalan-Dibene J, Mcintyre LL, Zlotnik A. Interleukin 30 to interleukin 40 [J]. J Interferon Cytokine Res, 2018, 38(10): 423-439.
[5] Ginaldi L, De Martinis M, Ciccarelli F, et al. Increased levels of interleukin 31(IL-31)in osteoporosis [J]. BMC Immunol, 2015, 16: 60. doi: 10.1186/s12865-015-0125-9.
[6] Ginaldi L, De Martinis M, Saitta S, et al. Interleukin-33 serum levels in postmenopausal women with osteoporosis [J]. Sci Rep, 2019, 9(1): 3786.
[7] Petra AI, Tsilioni I, Taracanova A, et al. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E [J]. Allergy Asthma Proc, 2018, 39(2): 153-160.
[8] Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis [J]. Int Immunol, 2010, 22(6): 453-467.
[9] Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [J]. Nat Immunol, 2004, 5(7): 752-760.
[10] Dambacher J, Beigel F, Seiderer J, et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease [J]. Gut, 2007, 56(9): 1257-1265.
[11] Lee CH, Hong CH, Yu WT, et al. Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis [J]. Br J Dermatol, 2012, 167(4): 794-803.
[12] Chattopadhyay S, Tracy E, Liang P, et al. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells [J]. J Biol Chem, 2007, 282(5): 3014-3026.
[13] Takayanagi H. Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption [J]. Nat Rev Rheumatol, 2015, 11(2): 74-76.
[14] 夏维波,章振林,林华,等. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 25(3): 281-309.
[15] Azizieh FY, Shehab D, Al JK, et al. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD [J]. J Inflamm Res, 2019, 12: 99-108. doi: 10.2147/JIR.S203590.
[16] Cop N, Ebo DG, Bridts CH, et al. Influence of IL-6, IL-33, and TNF-alpha on human mast cell activation: Lessons from single cell analysis by flow cytometry [J]. Cytometry B Clin Cytom, 2018, 94(3): 405-411.
[17] Stott B, Lavender P, Lehmann S, et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation [J]. J Allergy Clin Immunol, 2013, 132(2): 446-454.
[18] Schnittker D, Kwofie K, Ashkar A, et al. Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells [J]. Mediators Inflamm, 2013, 2013: 317503. doi: 10.1155/2013/317503.
[19] Rosine N, Etcheto A, Hendel-Chavez H, et al. Increase in Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis [J]. Sci Rep, 2018, 8(1): 7731.
[20] Cornelissen C, Luscher-Firzlaff J, Baron JM, et al. Signaling by IL-31 and functional consequences [J]. Eur J Cell Biol, 2012, 91(6-7): 552-566.
[21] Zhang Q, Putheti P, Zhou Q, et al. Structures and biological functions of IL-31 and IL-31 receptors [J]. Cytokine Growth Factor Rev, 2008, 19(5-6): 347-356.
[22] Perrigoue JG, Li J, Zaph C, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung [J]. J Exp Med, 2007, 204(3): 481-487.
[23] De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity [J]. FEBS Lett, 2005, 579(10): 2035-2039.
[24] Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective [J]. Int J Med Sci, 2012, 9(9): 825-832.
[25] Inada M, Miyaura C. Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis [J]. Clin Calcium, 2010, 20(10): 1467-1472.
[26] Ginaldi L, De Martinis M. Osteoimmunology and Beyond [J]. Curr Med Chem, 2016, 23(33): 3754-3774.
[27] Zoltowska NA, Lei Y, Adner M, et al. Mast cell-dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma [J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(3): 484-492.
[28] Saidi S, Bouri F, Lencel P, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling [J]. Cytokine, 2011, 53(3): 347-354.
[29] Schulze J, Bickert T, Beil FT, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells [J]. J Bone Miner Res, 2011, 26(4): 704-717.
[30] Velickovic M, Pejnovic N, Mitrovic S, et al. ST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in mice [J]. J Endod, 2015, 41(3): 369-375.
[31] Zaiss MM, Kurowska-Stolarska M, Bohm C, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss [J]. J Immunol, 2011, 186(11): 6097-6105.
[32] Taichman RS, Reilly MJ, Matthews LS. Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1alpha in response to interleukin 1beta and tumour necrosis factor alpha stimulation in vitro [J]. Br J Haematol, 2000, 108(2): 275-283.
[33] Da LF, Oliveira AP, Borges D, et al. The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease [J]. Mediators Inflamm, 2014, 2014: 342410. doi: 10.1155/2014/342410.
[34] Saleh H, Eeles D, Hodge JM, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro [J]. Endocrinology, 2011, 152(5): 1911-1922.
[35] Saluja R, Ketelaar ME, Hawro T, et al. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders [J]. Mol Immunol, 2015, 63(1): 80-85.
[36] Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 axis: a potential inflammatory pathway [J]. Mediators Inflamm, 2018, 2018: 3858032. doi: 10.1155/2018/3858032.
[37] Brylka LJ, Schinke T. Chemokines in physiological and pathological bone remodeling [J]. Front Immunol, 2019, 10: 2182. doi: 10.3389/fimmu.2019.02182.
[1] KANG Chengwei, LIU Lei, PU Xiaobing, TAN Gang, DONG Changchao, YAN Zhaokui. Analysis of bone metabolism and bone turnover markers in 62 cases of osteoporosis with subclinical hypothyroidism [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 82-86.
[2] XU Daxia, HOU Nan, LI Xiaofeng, WANG Chuang, KONG Meng, JIAO Guangjun, CHEN Yunzhen. Relevance between bone metabolism of glucocorticoid-induced osteoporosis and duration of glucocorticoid treatment [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 103-107.
[3] ZHANG Jing, HAO Lanxiang, ZHANG Xiaochen, ZHANG Yonghong, FAN Shanshan, LIU Yan, JIANG Ling. Effects of bisphenol A on the bone mineral densities of vertebrate and femoral bone in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 36-40.
[4] FENG Xiaoyu, ZHANG Hongmei, CHE Xuanqiang, KANG Donghong. Therapeutic effects of human osteoblast-stimulating factor on osteoporosis of ovariectomized rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 8-12.
[5] YU Lei, LI Zhen. Expression of interleukin-33 and its function in the serum of patients with cerebrovascular disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 75-79.
[6] ZHANG Hong-mei1, WANG Yan2, KANG Dong-hong1, CAO Wei1, LIU Tao1, WANG Ping1. Bone mineral density of vertebra lumbalis and femur of adult men in Jinan city [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 67-70.
[7] CHENG Kai-hua1, ZHANG Li-xin2. Therapy and effect of GnHRa on sex hormone and bone mineral
density in patients with endometriosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 83-86.
[8] LIU Mei1， ZHANG Jun2， WANG Xu-xia3. Changes of the mineral density of the alveolar bone between T1DM and T2DM rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 53-.
[9] ZHANG Lei,LI Mu,QI Lei,CAI Zhong-xu,LI Yu-hua,SUN Yuan-liang. AGEs in the pathogenesis of diabetic osteoporosis and the preventive mechanism of insulin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(11): 1148-1152.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] HUANG Fei,WANG Huaijing,XING Yi,GAO Wei,LI Yonggang,XING Ziying,LI Zhenzhong. Protective effects of NGF and GM1 on primary sensory neurons in SD rat with sciatic nerve injury[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(4): 332 -335 .
[2] JIANG Bao-dong,MA Xiang-xing,WANG Qing,WANG Qian,FENG Xiao-yuan,LI Ke,YU Fu-hua. Imaging parameters of multislice spiral CT venography in cerebral veins[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1084 -1086 .
[3] LYU Longfei, LI Lin, LI Shuhai, QI Lei, LU Ming, CHENG Chuanle, TIAN Hui. Application of laparoscopic fine needle catheter jejunostomy in minimally invasive McKeown resection of esophageal cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 77 -81 .
[4] SHAO Haigang, WANG Xuan, WANG Qing. Anatomy of the root canal system of mandibular first premolar in population of Shandong Province[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 85 -89 .
[5] LI Wei,LI Dao-wei,YE Qian,GAO Shun-cui,JIANG Shu-juan.

Diagnostic value of transbronchial needle aspiration in paratracheal mediastinal lesions

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1063 -1065 .
[6] TANG Fang1,2, ZHANG Yingqian3, WANG Zhiqiang4, KANG Dianmin4,
WANG Jiezhen1, XUE Fuzhong1. A 2D minimal spanning tree model of the spatial structures of natural focal disease[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 106 -110 .
[7] WANG Xu-ping,ZHAO Ling,FENG Yu-xin,SHANG Lin-shan,LIU Jin-cheng,. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(6): 564 -567 .
[8] WANG Xue-ping,YANG Hong-ling. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, (2): 213 .
[9] LI Yu-liang,WANG Yong-zheng,WANG Xiao-hua,ZHANG Fu-jun,ZHU Li-dong,ZHANG Wang-ming,LI Zheng,LI Zhen-jia,ZHANG Kai-xian. I implantation combined with Gemcitabine in the treatment of advanced pancreatic cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(4): 393 -396 .
[10] ZHU Xiaoli1, GUO Shuling1, SU Lei1, FENG Yuxin2, YUAN Fangshu1. Extraction of total proteins from demodex and qualification of their molecular weights[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 58 -62 .
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd